Boule has signed a long-term supply agreement with one of the company’s major OEM clients

Boule Diagnostics AB has extended a longstanding partnership with a global leader in the diagnostics sector providing products and services for the hematology markets. The parties have signed a supply agreement with an initial term of 10 years, and potential renewal for an additional 10 years, for reagents to be used on a new hematology platform that will be sold globally. Boule has worked with this partner for 20 years and have developed a strong technical R&D partnership and a very close and cooperative commercial relationship for production.

The partners will make a joint investment in automated manufacturing equipment in order to produce the reagents in a cost-effective manner. Production will begin at Boule’s production site in Florida with the potential to utilize other Boule production sites as needed. 

Boule’s OEM business accounted for about 10 percent of the Group’s net sales in 2019. The agreement secures recurring revenue for Boule over the next 10-20 years. During the initial years, these products will replace existing products. Thereafter future revenues are dependent on the success of the new platform’s international launch and sales.  

“Boule has an active and successful OEM portfolio to complement its strong global brand business. This new agreement demonstrates the client’s continued confidence in Boule to manufacture high quality products to meet their global marketing and distribution needs and aligns with our strategic initiative to grow our OEM business.” comments Boule’s CEO, Jesper Söderqvist.

For further information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone. +46 (0)70-689 05 90
Christina Rubenhag, CFO, Boule Diagnostics AB, phone +46 (0)70-546 72 22

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011. http://www.boule.com

The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 31, 2020.

Release